Neoplasms

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Rare Diseases

Lymphoma

Leukemia

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Leukemia, Lymphoid

Primary Myelofibrosis

Neoplasms by Histologic Type

Hematologic Diseases

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Lymphosarcoma

Acute Lymphoblastic Leukemia

Lymphoblastic Lymphoma

Acute Graft Versus Host Disease

Antineoplastic Agents

All Drugs and Chemicals

Venetoclax

Navitoclax

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to navitoclax prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

Expanded Access to Navitoclax

AbbVie

Skin and Connective Tissue Diseases

Diseases and Abnormalities at or Before Birth

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Gland and Hormone Related Diseases

Breast Neoplasms

Triple Negative Breast Neoplasms

Congenital Abnormalities

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial

Breast Diseases

Skin Diseases

Ovarian Cancer

Ovarian Epithelial Cancer

Veliparib

Poly(ADP-ribose) Polymerase Inhibitors

Enzyme Inhibitors

ABBVIE INC.

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to veliparib prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria. EAP is also available for other indications where there is reasonable scientific basis for efficacy.

Expanded Access to Veliparib

Respiratory Tract (Lung and Bronchial) Diseases

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma

Carcinoma, Bronchogenic

Bronchial Neoplasms

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

ABBV-400

ABBVIE CALL CENTER

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to ABBV-400 prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

Expanded Access to ABBV-400

Heart and Blood Diseases

Symptoms and General Pathology

Nutritional and Metabolic Diseases

Multiple Myeloma

Neoplasms, Plasma Cell

Leukemia, Myeloid

Leukemia, Myeloid, Acute

Leukemia, Lymphocytic, Chronic, B-Cell

Amyloidosis

Leukemia, Plasma Cell

Hemostatic Disorders

Blood Coagulation Disorders

Vascular Diseases

Paraproteinemias

Blood Protein Disorders

Hemorrhagic Disorders

Leukemia, B-Cell

Chronic Disease

Disease Attributes

Proteostasis Deficiencies

Metabolic Diseases

Myeloid Leukemia

Acute Myeloid Leukemia

Chronic Graft Versus Host Disease

Acute Non Lymphoblastic Leukemia

Chronic Lymphocytic Leukemia

Plasma Cell Leukemia

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Venetoclax prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

Expanded Access to Venetoclax

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Expanded Access to Navitoclax	NCT03592576	Myelofibrosis Acute Lymphocyt... Lymphoblastic L...	Navitoclax Venetoclax	4 Years -	AbbVie
Expanded Access to Veliparib	NCT03123211	Solid Tumors Wi... Triple Negative... High Grade Sero... Patients Requir...	Veliparib	-	AbbVie
Expanded Access to ABBV-400	NCT05982873	Non-Small Cell ...	ABBV-400	18 Years -	AbbVie
Expanded Access to Venetoclax	NCT03123029	Chronic Lymphoc... Multiple Myelom... Acute Myeloid L... Non-Hodgkin's L... Acute Lymphobla... Amyloidosis Plasma Cell Leu...	Venetoclax	-	AbbVie
Expanded Access to Venetoclax	NCT03123029	Chronic Lymphoc... Multiple Myelom... Acute Myeloid L... Non-Hodgkin's L... Acute Lymphobla... Amyloidosis Plasma Cell Leu...	Venetoclax	-	AbbVie

Spots Global Cancer Trial Database for special access scheme